Internal group headed by Principal Deputy Commissioner Rachel Sherman will develop implementation recommendations, which could include new guidance, regulations, a Q&A document or ‘nothing at all,’ Commissioner Gottlieb tells BIO annual meeting; he promises consultation with the law’s supporters and critics on Capitol Hill ‘to fully understand what the intent was with different provisions.’
The US FDA’s implementation of the federal right-to-try law will include plenty of outreach to the measure’s congressional backers and opponents, but the substance of the agency’s plan likely will not be clear for several months.
FDA Commissioner Scott Gottlieb told the 2018 BIO International Convention the agency is still figuring out how to implement the...